Cronos Group Posts Fourth Straight Quarter Of Gross Losses In Q3 2020

Cronos Group (TSX: CRON) (NASDAQ: CRON) this morning reported its third quarter financial results for the period ended September 30, 2020. The company reported net revenues of $11.4 million for the period, along with a net income of $68.5 million, primarily a result of a gain on derivative liabilities with the firm actually posting negative gross margins for the fourth quarter in a row.

Despite the climb in net revenues of 14.9%, the company saw its cost of sales rise even higher, resulting in a gross loss of $1.5 million for the quarter. Operating expenses did not fair much better, with the company reporting expenses of $39.6 million for the period, as compared to $31.8 million in the second quarter.

In terms of the breakdown of expenses, general and administrative made up the bulk of expenditures at $18.9 million, while share based payments amounted to $7.9 million and sales and marketing expenses totaled out at $7.2 million. The result, is that it appears the company needs to make some hard decisions as a means of getting its expenditures to manageable levels, and in line with the revenues that it is generating.

The quarter was essentially “saved” as a function of Cronos’ other income, which includes interest income of $3.8 million – roughly equivalent to 33% of the net revenues the company generated during the quarter. The big ticket item here however is the gain on revaluation of derivative liabilities, which amounted to $105.3 million. In layman terms, the company posted a net income due to its share price falling due to these derivative liabilities. Net income for the quarter overall as a result amount to $68.5 million.

Looking to the balance sheet, the firms cash position was relative unchanged, falling to $1,097 million from that of $1,109 million over the course of the quarter. Short term investments declined to $202.8 million from $213.6 million, while accounts receivables climbed to $6.1 million from $3.5 million. Inventory improved slightly as well to $56.4 million, from $53.2 million. Total current assets overall declined to $1,394.0 million from $1,401.9 million.

Liabilities meanwhile fell fairly significantly, a result again of the gain on derivative liabilities. Derivative liabilities fell to $102.7 million overall, down from $205.7 in the prior quarter. Accounts payable meanwhile rose to $39.0 million from $28.3 million. Overall, total current liabilities fell to $142.9 million, from that of $235.2 million over the course of the three month period.

Cronos Group last traded at $5.54 on the Nasdaq.


Information for this briefing was found via Sedar and Cronos Group. The author has no securities or affiliations related to these organizations. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Agnico Q1 Earnings Results Overshadowed By A Sinking Gold Price

Why More People Are Starting to Feel Broke | Darrell Thomas – VRIC Media

Newmont Q1 Earnings: A Billion In Free Cash Flow… A Month!

Recommended

Selkirk Copper Strikes New Lens Beneath Old Pit, Launches 50,000 Metre Phase 2 Program

Silver47 Pulls High-Grade Gold and Silver Assays from Nevada Vein Network At Kennedy

Related News

Cronos Pays OSC $1.3 Million As Penalty For Accounting Fraud, Settles SEC Charges

A Capital Markets Tribunal panel yesterday accepted a settlement agreement between the Ontario Securities Commission...

Tuesday, October 25, 2022, 11:01:00 AM

Cronos Group To Close Winnipeg Fermentation Facility, Cuts Guidance

Cronos Group (TSX: CRON) appears to be falling apart at the seams following the discontinuance...

Tuesday, August 8, 2023, 08:56:38 AM

Are Big Liquor And Tobacco Bankrolling Cannabis, Or Killing It?

Markets have been unkind to cannabis investors, and made certain fundamentals-based business bloggers, who were...

Saturday, June 6, 2020, 12:13:26 PM

Did Cronos Group Management Personally Benefit from the Redwood Acquisition?

This morning, Twitter user @xb0y posted findings related to a potentially undisclosed insider transaction related...

Monday, September 9, 2019, 11:10:04 AM

Medipharm Labs and Cronos Group Sign Second Manufacturing Agreement

Medipharm Labs (TSX: LABS) and Cronos Group (TSX: CRON) (NASDAQ: CRON) have entered into their...

Thursday, September 19, 2019, 09:23:17 AM